Search Results - "Schnadig, Ian D"

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial by Schwartzberg, Lee S, Dr, Modiano, Manuel R, MD, Rapoport, Bernardo L, MD, Chasen, Martin R, MD, Gridelli, Cesare, MD, Urban, Laszlo, MD, Poma, Allen, MD, Arora, Sujata, MSc, Navari, Rudolph M, MD, Schnadig, Ian D, MD

“…Summary Background Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic regimens and can occur for several days after…”
Get full text

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials by Rapoport, Bernardo L, Dr, Chasen, Martin R, MD, Gridelli, Cesare, MD, Urban, Laszlo, MD, Modiano, Manuel R, MD, Schnadig, Ian D, MD, Poma, Allen, MD, Arora, Sujata, MSc, Kansra, Vikram, PhD, Schwartzberg, Lee S, MD, Navari, Rudolph M, MD

“…Summary Background Highly emetogenic chemotherapy induces emesis in almost all patients in the absence of prophylaxis. Guidelines recommend use of a…”
Get full text

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy by Hesketh, Paul J., Schnadig, Ian D., Schwartzberg, Lee S., Modiano, Manuel R., Jordan, Karin, Arora, Sujata, Powers, Dan, Aapro, Matti

“…BACKGROUND Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and vomiting (CINV) in a…”
Get full text

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer by Sweeney, Christopher J, Percent, Ivor J, Babu, Sunil, Cultrera, Jennifer L, Mehlhaff, Bryan A, Goodman, Oscar B, Morris, David S, Schnadig, Ian D, Albany, Costantine, Shore, Neal D, Sieber, Paul R, Guba, Susan C, Zhang, Wei, Wacheck, Volker, Donoho, Gregory P, Szpurka, Anna M, Callies, Sophie, Lin, Boris Kin, Bendell, Johanna C

“…To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with…”
Get full text

Optimal timing of chemotherapy in androgen independent prostate cancer by Schnadig, Ian D., M.D, Beer, Tomasz M., M.D

“…Abstract Purpose To interpret available docetaxel clinical trial data in order to define optimal timing of the initiation of chemotherapy in androgen…”
Get full text

Patient‐physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer by Schnadig, Ian D., Fromme, Erik K., Loprinzi, Charles L., Sloan, Jeff A., Mori, Motomi, Li, Hong, Beer, Tomasz M.

“…BACKGROUND. Physician‐reported performance status (PS) is an important prognostic factor and frequently influences treatment decisions. To the authors'…”
Get full text

APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy by Schnadig, Ian D, Agajanian, Richy, Dakhil, Christopher, Gabrail, Nashat Y, Smith, Robert E, Taylor, Charles, Wilks, Sharon T, Schwartzberg, Lee S, Cooper, William, Mosier, Michael C, Payne, J Yvette, Klepper, Michael J, Vacirca, Jeffrey L

“…APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV). We…”
Get full text

Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices by Schnadig, Ian D, Hutson, Thomas E, Chung, Hsingwen, Dhanda, Rahul, Halm, Melissa, Forsyth, Michael, Vogelzang, Nicholas J

“…Micro-Abstract Dosing patterns of first-line sunitinib and association with toxicities and clinical outcomes were retrospectively evaluated across 17 community…”
Get full text

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial by Schnadig, Ian D, Agajanian, Richy, Dakhil, Christopher, Gabrail, Nashat, Vacirca, Jeffrey, Taylor, Charles, Wilks, Sharon, Braun, Eduardo, Mosier, Michael C, Geller, Robert B, Schwartzberg, Lee, Vogelzang, Nicholas

“…APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase…”
Get full text

Gastrointestinal stromal tumors: imatinib and beyond by Schnadig, Ian D, Blanke, Charles D

“…Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Clinicians previously classified GISTs as…”
Get full text

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy by Powers, Daniel, Schnadig, Ian D., Modiano, Manuel R., Arora, Sujata, Schwartzberg, Lee Steven

“…Abstract only 208 Background: Rolapitant, a novel NK-1 receptor antagonist, demonstrated efficacy in the prevention of CINV in pts receiving moderately- or…”
Get full text

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non–anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC) by Powers, Daniel, Hesketh, Paul Joseph, Schwartzberg, Lee Steven, Modiano, Manuel R., Arora, Sujata, Schnadig, Ian D.

“…Abstract only 209 Background: Rolapitant, a novel NK-1 receptor antagonist, showed efficacy in CINV prevention in patients (pts) receiving MEC…”
Get full text

Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC) by Armstrong, Andrew J., Olsson, Carl A, Schnadig, Ian D., Concepcion, Raoul S, Vacirca, Jeffrey L., Tutrone, Ronald F, Dakhil, Shaker R., Chang, Nancy N., Tang, Hong, Brown, Bruce, Vogelzang, Nicholas J.

“…Abstract only 177 Background: Managing patients ≥ 80 years old (yo) with mCRPC is challenging, given the high prevalence of comorbidities, polypharmacy, organ…”
Get full text

Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers by Navari, Rudolph M., Jordan, Karin, Rapoport, Bernardo Leon, Schnadig, Ian D., Chasen, Martin, Arora, Sujata, Powers, Daniel, Schwartzberg, Lee Steven

“…Abstract only 222 Background: Rolapitant (VARUBI) is a selective, long-acting neurokinin-1 receptor antagonist (RA) for the prevention of CINV. Rolapitant…”
Get full text

Clinical decision support tools (CDST) provide education at the point-of-care to assist provider treatment choices by Ginsburg, Aimee, Wilfong, Lalan S., Denduluri, Neelima, Howell, Josh, Dickens, Andrea, Casey, Kelly Leigh, Hsieh, Angela, Burke, John M., Cowey, Charles Lance, Hoverman, J. Russell, Knowles, Lynne M., Konduri, Kartik, Larson, Tim, Paulson, Andrew Scott, Schnadig, Ian D., Andorsky, David Jacob, Neubauer, Marcus A., Patt, Debra A.

“…Abstract only e19165 Background: Cancer care is complex and requires synthesis of increasing amounts of clinical and financial data to optimize treatment…”
Get full text

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy by Schnadig, Ian D., Modiano, Manuel R., Poma, Allen, Arora, Sujata, Schwartzberg, Lee Steven

“…Abstract only…”
Get full text

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC) by Hesketh, Paul Joseph, Schwartzberg, Lee Steven, Modiano, Manuel R., Arora, Sujata, Poma, Allen, Schnadig, Ian D.

“…Abstract only…”
Get full text

Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone by Sweeney, Christopher, Percent, Ivor John, Babu, Sunil, Cultrera, Jennifer, Mehlhaff, Bryan Allyn, Goodman, Oscar B., Morris, David, Schnadig, Ian D., Albany, Costantine, Shore, Neal D., Sieber, Paul R, Guba, Susan, Wang, Minmin, Kang, Suhyun, Wacheck, Volker, Donoho, Gregory P, Szpurka, Anna M., Callies, Sophie, Lin, Boris K., Bendell, Johanna C.

“…Abstract only 5009 Background: Preclinical and phase 1 results suggest PI3K/mTOR pathway inhibition may enhance androgen receptor inhibition. We report the…”
Get full text

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC) by Rapoport, Bernardo Leon, Schwartzberg, Lee Steven, Chasen, Martin Robert, Powers, Daniel, Arora, Sujata, Navari, Rudolph M., Schnadig, Ian D.

“…Abstract only 210 Background: The long-acting neurokinin-1 receptor antagonist (NK-1 RA) rolapitant has demonstrated efficacy for CINV prevention in patients…”
Get full text

Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) by Sonpavde, Guru, Bhor, Menaka, Hennessy, Daniel, Bhowmik, Debajyoti, Shen, Liji, Schnadig, Ian D.

“…Abstract only 223 Background: The impact of number of lines of therapy on outcomes following docetaxel (D) in metastatic castration-resistant prostate cancer…”
Get full text